Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proleukin in refractory chronic GVHD
NCT02318082Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2015
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of aldesleukin in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Feb 2015; status: completed.
02
Drugs
aldesleukin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02318082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318082.